Advances in toxicology and medical treatment of chemical warfare nerve agents
Tóm tắt
Từ khóa
Tài liệu tham khảo
Balali-Mood M, Balali-Mood K: Neurotoxic disorders of organophosphorus compounds and their managements. Arch Iran Med. 2008, 11: 65-89.
Gunderson CH, Lehmann CR, Sidell FR, Jabbari B: Nerve agents: a review. Neurology. 1992, 42: 946-950. 10.1212/WNL.42.5.946.
Bajgar J: Complex view on poisoning with nerve agents and organophosphates. Acta Medica (Hradec Kralove). 2005, 48: 3-21.
Balali-Mood M, Saber H: Recent advances in the treatment of organophosphorous poisonings. IJMS. 2012, 37: 74-91.
Leikin JB, Thomas RG, Walter FG, Klein R, Meislin HW: A review of nerve agent exposure for the critical care physician. Crit Care Med. 2002, 30: 2346-2354. 10.1097/00003246-200210000-00026.
OPCW: Report of sixteen session of the scientific advisory board. Book Report of sixteen session of the scientific advisory board. pp. Available at: http://www.opcw.org/index.php?eID=dam_frontend_push&docID=14882. City; 4–6 April 2011.
Stewart CE: Weapons of mass casualties and terrorism response handbook. 2006, London: Jones and Bartlett
Balali-Mood M, Balali-Mood K, Hosseini Shirazi F: Recent advances in treatment of acute organophosphorous nerve agents poisoning. IJPR. 2006, 5: 79-87.
Sidell FR, Borak J: Chemical warfare agents: II. Nerve agents. Ann Emerg Med. 1992, 21: 865-871. 10.1016/S0196-0644(05)81036-4.
Marrs TC, Maynard RL, Sidell FR: Organophosphate nerve agents. Chemical warfare agents: toxicology and treatment. Edited by: Marrs TC, Maynard RL, Sidell FR. 1996, New York: Wiley, 83-100.
Balali-Mood M, Shariat M: Treatment of organophosphate poisoning. Experience of nerve agents and acute pesticide poisoning on the effects of oximes. J Physiol Paris. 1998, 92: 375-378. 10.1016/S0928-4257(99)80008-4.
Black RM, Clarke RJ, Read RW, Reid MT: Application of gas chromatography–mass spectrometry and gas chromatography-tandem mass spectrometry to the analysis of chemical warfare samples, found to contain residues of the nerve agent sarin, sulphur mustard and their degradation products. J Chromatogr A. 1994, 662: 301-321. 10.1016/0021-9673(94)80518-0.
Sidell FR, Maynard RL, Marrs TC: Chemical warfare agents: toxicology and treatment. 2007, London: Wiley-Blackwell, an imprint of John Wiley & Sons Ltd, 2 Revised
Delfino RT, Ribeiro TS, Figueroa-Villar JD: Organophosphorus Compounds as Chemical Warfare Agents: a Review. J Braz Chem Soc. 2009, 20: 407-428.
Jokanovic M: Current understanding of the mechanisms involved in metabolic detoxification of warfare nerve agents. Toxicol Lett. 2009, 188: 1-10. 10.1016/j.toxlet.2009.03.017.
Takafuji ET, Kok AB: The chemical warfare threat and the military healthcare provider. Textbook of military medicine Part I Warfare, weaponry, and the wasualty medical aspects of chemical and biological warfare. Edited by: Zajtchuk R, Bellamy RF, Sidell FR. 1997, Washington, DC: Borden Institute, Walter Reed Medical Center, 111-128.
Material Safety Data Sheet Lethal Nerve Agent Sarin (GB). Available at: http://www.gulfweb.org/bigdoc/report/appgb.html. Accessed Aguest 13, 2012
Volans AP: Sarin: guidelines on the management of victims of a nerve gas attack. J Accid Emerg Med. 1996, 13: 202-206. 10.1136/emj.13.3.202.
Park SE, Kim ND, Yoo YH: Acetylcholinesterase plays a pivotal role in apoptosome formation. Cancer Res. 2004, 64: 2652-2655. 10.1158/0008-5472.CAN-04-0649.
Jokanovic M: Medical treatment of acute poisoning with organophosphorus and carbamate pesticides. Toxicol Lett. 2009, 190: 107-115. 10.1016/j.toxlet.2009.07.025.
Mumford H, Troyer JK: Post-exposure therapy with recombinant human BuChE following percutaneous VX challenge in guinea-pigs. Toxicol Lett. 2011, 206: 29-34. 10.1016/j.toxlet.2011.05.1016.
Lenz DE, Yeung D, Smith JR, Sweeney RE, Lumley LA, Cerasoli DM: Stoichiometric and catalytic scavengers as protection against nerve agent toxicity: a mini review. Toxicology. 2007, 233: 31-39. 10.1016/j.tox.2006.11.066.
Worek F, Eyer P, Aurbek N, Szinicz L, Thiermann H: Recent advances in evaluation of oxime efficacy in nerve agent poisoning by in vitro analysis. Toxicol Appl Pharmacol. 2007, 219: 226-234. 10.1016/j.taap.2006.10.001.
Jokanovic M: Biotransformation of organophosphorus compounds. Toxicology. 2001, 166: 139-160. 10.1016/S0300-483X(01)00463-2.
Worek F, Koller M, Thiermann H, Szinicz L: Diagnostic aspects of organophosphate poisoning. Toxicology. 2005, 214: 182-189. 10.1016/j.tox.2005.06.012.
Jokanovic M, Kosanovic M, Maksimovic M: Interaction of organophosphorus compounds with carboxylesterases in the rat. Arch Toxicol. 1996, 70: 444-450. 10.1007/s002040050297.
Gupta RC, Patterson GT, Dettbarn WD: Acute tabun toxicity; biochemical and histochemical consequences in brain and skeletal muscles of rat. Toxicology. 1987, 46: 329-341. 10.1016/0300-483X(87)90213-7.
Bajgar J: Organophosphates/nerve agent poisoning: mechanism of action, diagnosis, prophylaxis, and treatment. Adv Clin Chem. 2004, 38: 151-216.
Talbot BG, Anderson DR, Harris LW, Zarbrough LW, Lennox WJ: A comparison of in vivo and in vitro rates of ageing of soman-inhibited erythrocyte acetylcholinesterase in different animal species. Drug Chem Toxicol. 1988, 11: A comparison of in vivo and in vitro rates of ageing of soman-inhibited erythrocyte acetylcholinesterase in different animal species
Jokanovic M: Role of carboxylesterase in soman, sarin and tabun poisoning in rats. Pharmacol Toxicol. 1989, 65: 181-184. 10.1111/j.1600-0773.1989.tb01152.x.
Fonnum F, Sterri SH: Factors modifying the toxicity of organophosphorous compounds including Soman and Sarin. Fundam Appl Toxicol. 1981, 1: 143-147.
Clement JG, Copeman HT: Soman and sarin induce a long-lasting naloxone-reversible analgesia in mice. Life Sci. 1984, 34: 1415-1422. 10.1016/0024-3205(84)90055-9.
Duysen EG, Li B, Xie W, Schopfer LM, Anderson RS, Broomfield CA, Lockridge O: Evidence for nonacetylcholinesterase targets of organophosphorus nerve agent: supersensitivity of acetylcholinesterase knockout mouse to VX lethality. J Pharmacol Exp Ther. 2001, 299: 528-535.
Cowan FM, Shih TM, Lenz DE, Madsen JM, Broomfield CA: Hypothesis for synergistic toxicity of organophosphorus poisoning-induced cholinergic crisis and anaphylactoid reactions. J Appl Toxicol. 1996, 16: 25-33. 10.1002/(SICI)1099-1263(199601)16:1<25::AID-JAT303>3.0.CO;2-5.
Bajgar J: Present views on toxidynamics of soman poisoning. Acta Med (Hradec Kralove). 1996, 39: 101-105.
Tonkopii V: Oxidative stress in the mechanism of organophosphates neurotoxicity. Toxicol Lett. 2003, 144: 132-
Lotti M: Organophosphorus compounds. Experimental and clinical neurotoxicology. Edited by: Spencer PS, Schaumburg HH. 2000, New York: Oxford University Press, 898-925. 2
van Helden HP, Bueters TJ: Protective activity of adenosine receptor agonists in the treatment of organophosphate poisoning. Trends Pharmacol Sci. 1999, 20: 438-441. 10.1016/S0165-6147(99)01395-4.
Munro N: Toxicity of the organophosphate chemical warfare agents GA, GB, and VX: implications for public protection. Environ Health Perspect. 1994, 102: 18-38. 10.1289/ehp.9410218.
Cao CJ, Mioduszewski RJ, Menking DE, Valdes JJ, Katz EJ, Eldefrawi ME, Eldefrawi AT: Cytotoxicity of organophosphate anticholinesterases. In Vitro Cell Dev Biol Anim. 1999, 35: 493-500. 10.1007/s11626-999-0059-8.
Rickell DJ, Glenn JF, Houston WE: Medical defense against nerve agents: New direction. Milit Med. 1987, 152: 35-41.
van der Schans MJ, Polhuijs M, van Dijk C, Degenhardt CE, Pleijsier K, Langenberg JP, Benschop HP: Retrospective detection of exposure to nerve agents: analysis of phosphofluoridates originating from fluoride-induced reactivation of phosphylated BuChE. Arch Toxicol. 2004, 78: 508-524.
Minami M, Hui DM, Katsumata M, Inagaki H, Boulet CA: Method for the analysis of the methylphosphonic acid metabolites of sarin and its ethanol-substituted analogue in urine as applied to the victims of the Tokyo sarin disaster. J Chromatogr B Biomed Sci Appl. 1997, 695: 237-244. 10.1016/S0378-4347(97)00203-X.
van der Schans MJ, Lander BJ, van der Wiel H, Langenberg JP, Benschop HP: Toxicokinetics of the nerve agent (+/−)-VX in anesthetized and atropinized hairless guinea pigs and marmosets after intravenous and percutaneous administration. Toxicol Appl Pharmacol. 2003, 191: 48-62. 10.1016/S0041-008X(03)00216-3.
Military chemistry and chemical compounds. Field manual.Army. 1975, Washington, DC: Department of the Air Force
Munro NB, Talmage SS, Griffin GD, Waters LC, Watson AP, King JF, Hauschild V: The sources, fate, and toxicity of chemical warfare agent degradation products. Environ Health Perspect. 1999, 107: 933-974. 10.1289/ehp.99107933.
Reynolds ML, Little PJ, Thomas BF, Bagley RB, Martin BR: Relationship between the biodisposition of [3H]soman and its pharmacological effects in mice. Toxicol Appl Pharmacol. 1985, 80: 409-420. 10.1016/0041-008X(85)90385-0.
Polak RL, Cohen EM: The binding of sarin in the blood plasma of the rat. Biochem Pharmacol. 1970, 19: 877-881. 10.1016/0006-2952(70)90250-9.
Polak RL, Cohen EM: The influence of triorthocresylphosphate on the distribution of 32P in the body of the rat after the injection of 32P-sarin. Biochem Pharmacol. 1969, 18: 813-820. 10.1016/0006-2952(69)90051-3.
Little PJ, Reynolds ML, Bowman ER, Martin BR: Tissue disposition of [3H]sarin and its metabolites in mice. Toxicol Appl Pharmacol. 1986, 83: 412-419. 10.1016/0041-008X(86)90223-1.
Little PJ, Scimeca JA, Martin BR: Distribution of [3H] diisopropyl fluorophosphate, [3H]soman, [3H]sarin, and their metabolites in mouse brain. Drug Metab Dispos. 1988, 16: 515-520.
Nakajima T, Sasaki K, Ozawa H, Sekjima Y, Morita H, Fukushima Y, Yanagisawa N: Urinary metabolites of sarin in a patient of the Matsumoto sarin incident. Arch Toxicol. 1998, 72: 601-603. 10.1007/s002040050549.
Allert M, Rizk SS, Looger LL, Hellinga HW: Computational design of receptors for an organophosphate surrogate of the nerve agent soman. Proc Natl Acad Sci U S A. 2004, 101: 7907-7912. 10.1073/pnas.0401309101.
Tsuchihashi H, Katagi M, Nishikawa M, Tatsuno M: Identification of metabolites of nerve agent VX in serum collected from a victim. J Anal Toxicol. 1998, 22: 383-388.
Noort D, Hulst AG, Platenburg DH, Polhuijs M, Benschop HP: Quantitative analysis of O-isopropyl methylphosphonic acid in serum samples of Japanese citizens allegedly exposed to sarin: estimation of internal dosage. Arch Toxicol. 1998, 72: 671-675. 10.1007/s002040050559.
Noort D, Benschop HP, Black RM: Biomonitoring of exposure to chemical warfare agents: a review. Toxicol Appl Pharmacol. 2002, 184: 116-126. 10.1006/taap.2002.9449.
Wang J, Timchalk C, Lin Y: Carbon nanotube-based electrochemical sensor for assay of salivary cholinesterase enzyme activity: an exposure biomarker of organophosphate pesticides and nerve agents. Environ Sci Technol. 2008, 42: 2688-2693. 10.1021/es702335y.
Marsillach J, Richter RJ, Kim JH, Stevens RC, MacCoss MJ, Tomazela D, Suzuki SM, Schopfer LM, Lockridge O, Furlong CE: Biomarkers of organophosphorus (OP) exposures in humans. Neurotoxicology. 2011, 32: 656-660. 10.1016/j.neuro.2011.06.005.
John H, Breyer F, Thumfart JO, Hochstetter H, Thiermann H: Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) for detection and identification of albumin phosphylation by organophosphorus pesticides and G- and V-type nerve agents. Anal Bioanal Chem. 2010, 398: 2677-2691. 10.1007/s00216-010-4076-y.
Jakubowski M, Heykamp LS, Durst HD, Thomson SA: Preliminary studies in the formation of ethyl methylphosphonofluoridate from rat and human serum exposed to VX and treated with fluoride ion. Anal Lett. 2001, 4: 727-747.
Black RM: History and perspectives of bioanalytical methods for chemical warfare agent detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2010, 878: 1207-1215. 10.1016/j.jchromb.2009.11.025.
Polhuijs M, Langenberg JP, Benschop HP: New method for retrospective detection of exposure to organophosphorus anticholinesterases: application to alleged sarin victims of Japanese terrorists. Toxicol Appl Pharmacol. 1997, 146: 156-161. 10.1006/taap.1997.8243.
Matsuda Y, Nagao M, Takatori T, Niijima H, Nakajima M, Iwase H, Kobayashi M, Iwadate K: Detection of the sarin hydrolysis product in formalin-fixed brain tissues of victims of the Tokyo subway terrorist attack. Toxicol Appl Pharmacol. 1998, 150: 310-320. 10.1006/taap.1998.8428.
Fidder A, Hulst AG, Noort D, de Ruiter R, van der Schans MJ, Benschop HP, Langenberg JP: Retrospective detection of exposure to organophosphorus anti-cholinesterases: mass spectrometric analysis of phosphylated human butyrylcholinesterase. Chem Res Toxicol. 2002, 15: 582-590. 10.1021/tx0101806.
Balali-Mood M, Hefazi M: Comparison of early and late toxic effects of sulfur mustard in Iranian veterans. Basic Clin Pharmacol Toxicol. 2006, 99: 273-282. 10.1111/j.1742-7843.2006.pto_429.x.
DM P: Environment committee armed forces epidemiological board long-term health effects associated with sub-clinical exposures to GB and mustard. 1996, Gulf link: Office of the special assistant for Gulf War Illnesses,Available at: http://www.gul_ink.osd.mil/agent.html.
Rickett DL, Glenn JF, Beers ET: Central respiratory effects versus neuromuscular actions of nerve agents. Neurotoxicology. 1986, 7: 225-236.
Worek F, Kleine A, Falke K, Szinicz L: Arrhythmias in organophosphate poisoning: effect of atropine and bispyridinium oximes. Arch Int Pharmacodyn Ther. 1995, 329: 418-435.
Sidell FR: Soman and sarin: clinical manifestations and treatment of accidental poisoning by organophosphates. Clin Toxicol. 1974, 7: 1-17. 10.3109/15563657408987971.
Rengstorff RH: Accidental exposure to sarin: vision effects. Arch Toxicol. 1985, 56: 201-203. 10.1007/BF00333427.
Nozaki H, Hori S, Shinozawa Y, Fujishima S, Takuma K, Sagoh M, Kimura H, Ohki T, Suzuki M, Aikawa N: Secondary exposure of medical staff to sarin vapor in the emergency room. Intensive Care Med. 1995, 21: 1032-1035. 10.1007/BF01700667.
Marrs TC, Maynard RL, Sidell FR: Chemical warfare agents. Toxicology and treatment. 1996, Toronto: J. Wiley and Sons
US Army Medical Research Institute of Chemical Defense: Nerve agents. Medical management of chemical casualties handbook. 1998, Edgewood: Aberdeen Proving Ground, 3
Christensen MK, Crethull P, Crook JW, Oberst FW, Ross RS, Umland CW: Resuscitation of dogs poisoned by inhalation of the nerve gas GB. Mil Med. 1956, 119: 377-386.
Ludomirsky A, Klein HO, Sarelli P, Becker B, Hoffman S, Taitelman U, Barzilai J, Lang R, David D, DiSegni E, Kaplinsky E: Q-T prolongation and polymorphous ("torsade de pointes") ventricular arrhythmias associated with organophosphorus insecticide poisoning. Am J Cardiol. 1982, 49: 1654-1658. 10.1016/0002-9149(82)90242-9.
Singer AW, Jaax NK, Graham JS, McLeod CG: Cardiomyopathy in Soman and Sarin intoxicated rats. Toxicol Lett. 1987, 36: 243-249. 10.1016/0378-4274(87)90192-5.
Jalali N, Balali-Mood M, Jalali I, Shakeri MT: Electrophysiological changes in patients with acute organophosphorous pesticide poisoning. Basic Clin Pharmacol Toxicol. 2012, 108: 251-255.
Sivam SP, Hoskins B, Ho IK: An assessment of comparative acute toxicity of diisopropyl-fluorophosphate, tabun, sarin, and soman in relation to cholinergic and GABAergic enzyme activities in rats. Fundam Appl Toxicol. 1984, 4: 531-538.
Balali-Mood M, Balali-Mood K: Nerve agents. Critical Care Toxicology. Edited by: Brent J. 2005, Philadelphia, USA: Elsevier Mosby, 1379-1393.
Heide EA: Cholinesterase inhibitors: Including insecticides and chemical warfare nerve agents Part 5: The intermediate syndrome. 2012, Agency for toxic substances and disease registry (ATSDR), Avalable at: http://www.atsdr.cdc.gov/csem/csem.asp?csem=11&po=28, 2012
Rickett D, Glenn J, Beers ET: Central respiratory effects versus neuromuscular actions of nerve agents. Neurotoxicology. 1953, 8: 466-475.
Schecter WP: Cholinergic symptoms due to nerve agent attack: a strategy for management. Anesthesiol Clin North America. 2004, 22: 579-590. 10.1016/j.atc.2004.04.005. viii
Abdollahi M, Karami-Mohajeri S: A comprehensive review on experimental and clinical findings in intermediate syndrome caused by organophosphate poisoning. Toxicol Appl Pharmacol. 2012, 258: 309-314. 10.1016/j.taap.2011.11.014.
Avasthi G, Singh G: Serial neuro-electrophysiological studies in acute organophosphate poisoning–correlation with clinical findings, serum cholinesterase levels and atropine dosages. J Assoc Physicians India. 2000, 48: 794-799.
Smith WJ, Clark MWG, Talbot TB, Caple PA, Sidell FR, Hurst CG: Chapter 9,Long-term health effects of chemical threat agents. Textbooks of military medicine ,medical aspects of chemical warfare. Edited by: Lenhart MK, Tuorinsky SD. 2008, Washington, DC: The Office of the Surgeon General at TMM Publications, 311-338.
Karalliedde L, Wheeler H, Maclehose R, Murray V: Possible immediate and long-term health effects following exposure to chemical warfare agents. Public Health. 2000, 114: 238-248.
Emerick GL, Peccinini RG, de Oliveira GH: Organophosphorus-induced delayed neuropathy: a simple and efficient therapeutic strategy. Toxicol Lett. 2010, 192: 238-244. 10.1016/j.toxlet.2009.10.032.
Jokanovic M, Kosanovic M, Brkic D, Vukomanovic P: Organophosphate induced delayed polyneuropathy in man: an overview. Clin Neurol Neurosurg. 2011, 113: 7-10. 10.1016/j.clineuro.2010.08.015.
Darchini-Maragheh E, Nemati-Karimooy H, Hasanabadi H, Balali-Mood M: Delayed Neurological Complications of Sulphur Mustard and Tabun Poisoning in 43 Iranian Veterans. Basic Clin Pharmacol Toxicol. 2012, 111: 426-432.
Balali-Mood M, Navaeian A: Clinical and paraclinical fndings in 233 patients with sulfur mustard poisoning. Proceedings of the second world congress on new compounds in biological and chemical warfare, toxicological evaluation. Edited by: Heyndrickx B. 1986, Ghent, Belgium: Ghent University Press, 464-473.
Engel CC, Jaffer A, Adkins J, Riddle JR, Gibson R: Can we prevent a second 'Gulf War syndrome'? Population-based healthcare for chronic idiopathic pain and fatigue after war. Adv Psychosom Med. 2004, 25: 102-122.
Masson P: Evolution of and perspectives on therapeutic approaches to nerve agent poisoning. Toxicol Lett. 2011, 206: 5-13. 10.1016/j.toxlet.2011.04.006.
Tang FR, Loke WK, Ling EA: Comparison of status epilepticus models induced by pilocarpine and nerve agents - a systematic review of the underlying aetiology and adopted therapeutic approaches. Curr Med Chem. 2011, 18: 886-899. 10.2174/092986711794927720.
Nakajima T, Sato S, Morita H, Yanagisawa N: Sarin poisoning of a rescue team in the Matsumoto sarin incident in Japan. Occup Environ Med. 1997, 54: 697-701. 10.1136/oem.54.10.697.
Fullerton CS, Ursano RJ: Behavioral and psychological responses to chemical and biological warfare. Mil Med. 1990, 155: 54-59.
Page WF: Long-term health effects of exposure to sarin and other anticholinesterase chemical warfare agents. Mil Med. 2003, 168: 239-245.
Grauer E, Chapman S, Rabinovitz I, Raveh L, Weissman BA, Kadar T, Allon N: Single whole-body exposure to sarin vapor in rats: long-term neuronal and behavioral deficits. Toxicol Appl Pharmacol. 2008, 227: 265-274. 10.1016/j.taap.2007.11.006.
Sidell FR, Newmark J, McDonough JH: Textbooks of military medicine ,medical aspects of chemical warfare. Edited by: Lenhart MK, Tuorinsky SD. 2008, Washington D.C: Department of the Army, United States of America, 155-219.
Oberst FW, Koon WS, Christensen MK, Crook JW, Cresthull P, Freeman G: Retention of inhaled sarin vapor and its effect on red blood cell cholinesterase activity in man. Clin Pharmacol Ther. 1968, 9: 421-427.
Baker MD: Antidotes for nerve agent poisoning: should we differentiate children from adults?. Curr Opin Pediatr. 2007, 19: 211-215. 10.1097/MOP.0b013e328012cba2.
Drug information online (drug.com). 2012, ATNAA. http://www.drugs.com/pro/atnaa.html
Marrs TC, Rice P, Vale JA: The role of oximes in the treatment of nerve agent poisoning in civilian casualties. Toxicol Rev. 2006, 25: 297-323. 10.2165/00139709-200625040-00009.
Brown MA, Brix KA: Review of health consequences from high-, intermediate- and low-level exposure to organophosphorus nerve agents. J Appl Toxicol. 1998, 18: 393-408. 10.1002/(SICI)1099-1263(199811/12)18:6<393::AID-JAT528>3.0.CO;2-0.
ATSDR: Medical management guidelines for Nerve Agents: Tabun (GA); Sarin (GB); Soman (GD); and VX. 2012, Agency for toxic substances and disease registry http://www.atsdr.cdc.gov/MHMI/mmg166.pdf
Robinson S, Magenis TP, Minter DI, Harper H: The effects of varying doses of atropine on temperature regulation of men and dogs. The Physiological Effects of Atropine and Potential Atropine Substitutes. Edited by: Robinson S. 1953, Edgewood Arsenal, MD: Medical Research Laboratories
Pangi B: Consequence management in the 1995 Sarin attacks on the Japanese subway system. Stud Confli Terrorri. 2002, 25: 421-448. 10.1080/10576100290101296.
Anonymus: ACT FAST,Agent Characteristics and Toxicology, First Aid and Special Treatment,Student gauidline. 2007, U.S. Department of the Army
Hurst CG: Decontamination. Textbooks of military medicine ,medical aspects of chemical warfare. Edited by: Lenhart MK, Tuorinsky SD. 2008, Washington D.C: Department of the Army, United States of America, 351-359.
Zheng X, Okolotowicz K, Wang B, Macdonald M, Cashman JR, Zhang J: Direct detection of the hydrolysis of nerve agent model compounds using a fluorescent probe. Chem Biol Interact. 2010, 187: 330-334. 10.1016/j.cbi.2010.01.027.
Dawson RM, Pantelidis S, Rose HR, Kotsonis SE: Degradation of nerve agents by an organophosphate-degrading agent (OpdA). J Hazard Mater. 2008, 157: 308-314. 10.1016/j.jhazmat.2007.12.099.
Balali Mood M, Balali Mood B, Moshiri M: Sulfur mustard. Encyclopedia of Toxicology. Edited by: Wexler P, Greim H, Moser V, Wiegand TJ, Lafarga JVT, Peyster A, Harper S, Abdollahi M, Gad SC, Ray SD. 2012, Elsevier, in press
Balali-Mood M, Ayati MH, Ali-Akbarian H: Effect of high doses of sodium bicarbonate in acute organophosphorous pesticide poisoning. Clin Toxicol (Phila). 2005, 43: 571-574. 10.1081/CLT-200068845.
Balali-Mood K, Bond PJ, Sansom MS: Interaction of monotopic membrane enzymes with a lipid bilayer: a coarse-grained MD simulation study. Biochemistry. 2009, 48: 2135-2145. 10.1021/bi8017398.
Moody RP, Maibach HI: Skin decontamination: Importance of the wash-in effect. Food Chemic Toxico. 2006, 44: 1783-1788. 10.1016/j.fct.2006.05.020.
Seto Y: Decontamination of chemical and biological warfare agents. Yakugaku Zasshi. 2009, 129: 53-69. 10.1248/yakushi.129.53.
Ishoj T, Jensen K: Chemical warfare poisoning in time of peace. Ugeskr Laeger. 1999, 161: 808-810.
Clarkson ED, Schulz SM, Railer RF, Smith KH: Median lethal dose determination for percutaneous exposure to soman and VX in guinea pigs and the effectiveness of decontamination with M291 SDK or SANDIA foam. Toxicolo Lette. 2012, 212: 282-287. 10.1016/j.toxlet.2012.05.028.
Bismuth C, Borron SW, Baud FJ, Barriot P: Chemical weapons: documented use and compounds on the horizon. Toxicolo Lette. 2004, 149: 11-18. 10.1016/j.toxlet.2003.12.016.
Cheng TC, DeFrank JJ, Rastogi VK: Alteromonas prolidase for organophosphorus G-agent decontamination. Chem Biol Interact. 1999, 119–120: 455-462.
Cheng TC, Calomiris JJ: A cloned bacterial enzyme for nerve agent decontamination. Enzy Microb Technolo. 1996, 18: 597-601. 10.1016/0141-0229(95)00152-2.
Ghanem E, Raushel FM: Detoxification of organophosphate nerve agents by bacterial phosphotriesterase. Toxicol Appl Pharmacol. 2005, 207: 459-470. 10.1016/j.taap.2005.02.025.
Gordon RK, Feaster SR, Russell AJ, LeJeune KE, Maxwell DM, Lenz DE, Ross MC, Doctor BP: Organophosphate skin decontamination using immobilized enzymes. Chem Biol Interact. 1999, 119–120: 463-470.
Wang RF, Wang TL: Nerve Agents. Disaster Med. 2005, 4 (Suppl 1): S29-S34.
ATSDR: Nerve agents (GA, GB, GD, VX). Agency for toxic substances and disease registry, division of toxicology. 2012,http://www.atsdr.cdc.gov/toxfaqs/tfacts166.pdf,
Hrobak PK: Nerve agents: implications for anesthesia providers. AANA J. 2008, 76: 95-97.
Barthold CL, Schier JG: Organic phosphorus compounds--nerve agents. Crit Care Clin. 2005, 21: 673-689. 10.1016/j.ccc.2005.05.010. v-vi
Newmark J: The birth of nerve agent warfare: lessons from Syed Abbas Foroutan. Neurology. 2004, 62: 1590-1596. 10.1212/01.WNL.0000124519.85516.50.
Eddleston M, Buckley NA, Checketts H, Senarathna L, Mohamed F, Sheriff MH, Dawson A: Speed of initial atropinisation in significant organophosphorus pesticide poisoning–a systematic comparison of recommended regimens. J Toxicol Clin Toxicol. 2004, 42: 865-875. 10.1081/CLT-200035223.
Kassa J: Therapeutic and neuroprotective efficacy of pharmacological pretreatment and antidotal treatment of acute tabun or soman poisoning with the emphasis on pretreatment drug PANPAL. Arh Hig Rada Toksikol. 2006, 57: 427-434.
McLaughlin B, Rickels K, Abidi M, Toro R: Meprobamate-benactyzine (Deprol) and placebo in two depressed outpatient populations. Psychosomatics. 1969, 10: 73-81.
Herz A, Teschemacher H, Hofstetter A, Kurz H: The Importance of Lipid-Solubility for the Central Action of Cholinolytic Drugs. Int J Neuropharmacol. 1965, 4: 207-218. 10.1016/0028-3908(65)90037-7.
McDonough JH, Zoeffel LD, McMonagle J, Copeland TL, Smith CD, Shih TM: Anticonvulsant treatment of nerve agent seizures: anticholinergics versus diazepam in soman-intoxicated guinea pigs. Epilepsy Res. 2000, 38: 1-14.
Eyer P: The role of oximes in the management of organophosphorus pesticide poisoning. Toxicol Rev. 2003, 22: 165-190. 10.2165/00139709-200322030-00004.
Kovacic P: Mechanism of organophosphates (nerve gases and pesticides) and antidotes: electron transfer and oxidative stress. Curr Med Chem. 2003, 10: 2705-2709. 10.2174/0929867033456314.
McDonough JH, Shih T-M: Neuropharmacological Mechanisms of Nerve Agent-induced Seizure and Neuropathology. Neurosci Biobehav Rev. 1997, 21: 559-579. 10.1016/S0149-7634(96)00050-4.
Kassa J: Review of oximes in the antidotal treatment of poisoning by organophosphorus nerve agents. J Toxicol Clin Toxicol. 2002, 40: 803-816. 10.1081/CLT-120015840.
Kassa J, Kuca K, Karasova J, Musilek K: The development of new oximes and the evaluation of their reactivating, therapeutic and neuroprotective efficacy against tabun. Mini Rev Med Chem. 2008, 8: 1134-1143. 10.2174/138955708785909871.
Mercey G, Verdelet T, Renou J, Kliachyna M, Baati R, Nachon F, Jean L, Renard PY: Reactivators of acetylcholinesterase inhibited by organophosphorus nerve agents. Acc Chem Res. 2012, 45: 756-766. 10.1021/ar2002864.
Rahimi R, Nikfar S, Abdollahi M: Increased morbidity and mortality in acute human organophosphate-poisoned patients treated by oximes: a meta-analysis of clinical trials. Hum Exp Toxicol. 2006, 25: 157-162. 10.1191/0960327106ht602oa.
Boskovic B, Kovacevic V, Jovanovic D: PAM-2 Cl, HI-6, and HGG-12 in soman and tabun poisoning. Fundam Appl Toxicol. 1984, 4: S106-115. 10.1016/0272-0590(84)90142-8.
Kuca K, Cabal J, Kassa J, Jun D, Hrabinova M: A comparison of the potency of the oxime HLo-7 and currently used oximes (HI-6, pralidoxime, obidoxime) to reactivate nerve agent-inhibited rat brain acetylcholinesterase by in vitro methods. Acta Medica (Hradec Kralove). 2005, 48: 81-86.
Kuca K, Cabal J, Kassa J, Jun D, Hrabinova M: In vitro potency of H oximes (HI-6, HLo-7), the oxime BI-6, and currently used oximes (pralidoxime, obidoxime, trimedoxime) to reactivate nerve agent-inhibited rat brain acetylcholinesterase. J Toxicol Environ Health A. 2006, 69: 1431-1440. 10.1080/15287390500364283.
Fusek J, Bajgar J: Treatment of intoxication with GV compound in laboratory rats. Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove. 1994, 37: 57-62.
Kassa J, Humlicek V: A comparison of the potency of newly developed oximes (K074, K075) and currently available oximes (obidoxime, trimedoxime, HI-6) to counteract acute toxic effects of tabun and cyclosarin in mice. Drug Chem Toxicol. 2008, 31: 127-135. 10.1080/01480540701688816.
Kassa J, Jun D, Kuca K, Bajgar J: Comparison of reactivating and therapeutic efficacy of two salts of the oxime HI-6 against tabun, soman and cyclosarin in rats. Basic Clin Pharmacol Toxicol. 2007, 101: 328-332. 10.1111/j.1742-7843.2007.00126.x.
Kassa J, Jun D, Kuca K: A comparison of reactivating efficacy of newly developed oximes (K074, K075) and currently available oximes (obidoxime, HI-6) in cyclosarin-and tabun-poisoned rats. J Enzyme Inhib Med Chem. 2007, 22: 297-300. 10.1080/14756360601114361.
Kassa J, Jun D, Karasova J, Bajgar J, Kuca K: A comparison of reactivating efficacy of newly developed oximes (K074, K075) and currently available oximes (obidoxime, HI-6) in soman, cyclosarin and tabun-poisoned rats. Chem Biol Interact. 2008, 175: 425-427. 10.1016/j.cbi.2008.05.001.
Bajgar J, Hajek P, Zdarova JK, Kassa J, Paseka A, Slizova D, Krs O, Kuca K, Jun D, Fusek J, Capek L: A comparison of tabun-inhibited rat brain acetylcholinesterase reactivation by three oximes (HI-6, obidoxime, and K048) in vivo detected by biochemical and histochemical techniques. J Enzyme Inhib Med Chem. 2010, 25: 790-797. 10.3109/14756360903433373.
Kuca K, Cabal J, Jung YS, Musilek K, Soukup O, Jun D, Pohanka M, Musilova L, Karasova J, Novotny L, Hrabinova M: Reactivation of human brain homogenate cholinesterases inhibited by Tabun using newly developed oximes K117 and K127. Basic Clin Pharmacol Toxicol. 2009, 105: 207-210. 10.1111/j.1742-7843.2009.00421.x.
Melchers BP, Philippens IH, Wolthuis OL: Efficacy of HI-6 and HLo-7 in preventing incapacitation following nerve agent poisoning. Pharmacol Biochem Behav. 1994, 49: 781-788. 10.1016/0091-3057(94)90223-2.
Cassel G, Karlsson L, Waara L, Ang KW, Goransson-Nyberg A: Pharmacokinetics and effects of HI 6 in blood and brain of soman-intoxicated rats: a microdialysis study. Eur J Pharmacol. 1997, 332: 43-52. 10.1016/S0014-2999(97)01058-3.
Clement JG, Hansen AS, Boulet CA: Efficacy of HLo-7 and pyrimidoxime as antidotes of nerve agent poisoning in mice. Arch Toxicol. 1992, 66: 216-219. 10.1007/BF01974018.
Shih TM, Guarisco JA, Myers TM, Kan RK, McDonough JH: The oxime pro-2-PAM provides minimal protection against the CNS effects of the nerve agents sarin, cyclosarin, and VX in guinea pigs. Toxicol Mech Methods. 2011, 21: 53-62. 10.3109/15376516.2010.529190.
Howland MA: Pyridoxine. Goldfrank's toxicologic emergencies. Edited by: Nelson L, Lewin N, Howland MA, Hoffman R, Goldfrank L, Flomenbaum NE. 2011, New York: McGroHill, ninth
Holstege CP, Dobmeier SG, Bechtel LK: Critical care toxicology. Emerg Medi Clini Nor Am. 2008, 26: 715-739. 10.1016/j.emc.2008.04.003.
Greaves I, Hunt P: Chapter 5: Chemical agents. Responding to terrorism. Edited by: Imre R, Mooney TB, Clarke B. 2010, Edinburgh: Churchill Livingstone, 233-344.
Mongan PD, Winkley J, Joseph HMI: Nerve and chemical agents. Hospital preparation for bioterror. 2006, Burlington: Academic Press, 73-88.
Kayouka M, Houzé P, Debray M, Baud FJ: Acute renal failure enhances the antidotal activity of pralidoxime towards paraoxon-induced respiratory toxicity. Toxicol Lett. 2009, 189: 48-56. 10.1016/j.toxlet.2009.04.020.
Kayouka M, Houzé P, Risède P, Debray M, Baud FJ: Acute renal failure alters the kinetics of pralidoxime in rats. Toxicol Lett. 2009, 184: 61-66. 10.1016/j.toxlet.2008.10.022.
Kassa J: Effect of diazepam on the effectiveness of antidote therapy in eliminating the acute lethal effects of soman in mice. Cas Lek Cesk. 2001, 140: 497-499.
Shih TM, Koviak TA, Capacio BR: Anticonvulsants for poisoning by the organophosphorus compound soman: pharmacological mechanisms. Neurosci Biobehav Rev. 1991, 15: 349-362. 10.1016/S0149-7634(05)80028-4.
Shih TM, Rowland TC, McDonough JH: Anticonvulsants for nerve agent-induced seizures: The influence of the therapeutic dose of atropine. J Pharmacol Exp Ther. 2007, 320: 154-161.
Joosen MJ, van der Schans MJ, van Helden HP: Percutaneous exposure to the nerve agent VX: Efficacy of combined atropine, obidoxime and diazepam treatment. Chem Biol Interact. 2010, 188: 255-263. 10.1016/j.cbi.2010.06.010.
McDonough JH: Midazolam: An Improved Anticonvulsant Treatment for Nerve Agent-Induced Seizures. 2002
McDonough JH, McMonagle J, Copeland T, Zoeffel D, Shih TM: Comparative evaluation of benzodiazepines for control of soman-induced seizures. Arch Toxicol. 1999, 73: 473-478. 10.1007/s002040050637.
Myhrer T, Enger S, Aas P: Anticonvulsant efficacy of drugs with cholinergic and/or glutamatergic antagonism microinfused into area tempestas of rats exposed to soman. Neurochem Res. 2008, 33: 348-354. 10.1007/s11064-007-9429-3.
Lallement G, Baubichon D, Clarencon D, Galonnier M, Peoc'h M, Carpentier P: Review of the value of gacyclidine (GK-11) as adjuvant medication to conventional treatments of organophosphate poisoning: primate experiments mimicking various scenarios of military or terrorist attack by soman. Neurotoxicology. 1999, 20: 675-684.
Smith JS, Fulop ZL, Levinsohn SA, Darrell RS, Stein DG: Effects of the novel NMDA receptor antagonist gacyclidine on recovery from medial frontal cortex contusion injury in rats. Neural Plast. 2000, 7: 73-91. 10.1155/NP.2000.73.
Hirbec H, Gaviria M, Vignon J: Gacyclidine: a new neuroprotective agent acting at the N-methyl-D-aspartate receptor. CNS Drug Rev. 2001, 7: 172-198.
Figueiredo TH, Qashu F, Apland JP, Aroniadou-Anderjaska V, Souza AP, Braga MF: The GluK1 (GluR5) Kainate/{alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology. J Pharmacol Exp Ther. 2011, 336: 303-312. 10.1124/jpet.110.171835.
Dorandeu F, Carpentier P, Baubichon D, Four E, Bernabe D, Burckhart MF, Lallement G: Efficacy of the ketamine-atropine combination in the delayed treatment of soman-induced status epilepticus. Brain Res. 2005, 1051: 164-175. 10.1016/j.brainres.2005.06.013.
Dhote F, Carpentier P, Barbier L, Peinnequin A, Baille V, Pernot F, Testylier G, Beaup C, Foquin A, Dorandeu F: Combinations of ketamine and atropine are neuroprotective and reduce neuroinflammation after a toxic status epilepticus in mice. Toxicol Appl Pharmacol. 2012, 259: 195-209. 10.1016/j.taap.2011.12.024.
Zhi QX, Yi FH, Xi CT: Huperzine A ameliorates the spatial working memory impairments induced by AF64A. Neurorep. 1995, 6: 2221-2224. 10.1097/00001756-199511000-00029.
Zhang JM, Hu GY: Huperzine A, a nootropic alkaloid, inhibits N-methyl-D-aspartate-induced current in rat dissociated hippocampal neurons. Neurosci. 2001, 105: 663-669. 10.1016/S0306-4522(01)00206-8.
Zangara A: The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease. Pharmacol Biochem Behav. 2003, 75: 675-686. 10.1016/S0091-3057(03)00111-4.
Coleman BR, Ratcliffe RH, Oguntayo SA, Shi X, Doctor BP, Gordon RK, Nambiar MP: [+]-Huperzine A treatment protects against N-methyl-D-aspartate-induced seizure/status epilepticus in rats. Chem Biol Interact. 2008, 175: 387-395. 10.1016/j.cbi.2008.05.023.
Grunwald J, Raveh L, Doctor BP, Ashani Y: Huperzine A as a pretreatment candidate drug against nerve agent toxicity. Life Sci. 1994, 54: 991-997. 10.1016/0024-3205(94)00501-X.
Garcia GE, Vernon A, Moorad-Doctor D, Ratcliffe RH: (−)Huperzine A, replacement for pyridostigmine bromide as nerve agent pretreatment, measured in Guinea Pig plasma by a new ultrahigh-pressure liquid chromatography (UHPLC)-MS method. FASEBJ. 2009, 23: Suppl
Nurulain SN: Different approaches to acute organophosphorus poison treatment. J Pak Med Assoc. 2012, 62: 712-717.
Antonijvic B, Stefanovic D, Milovanovic ZA, Stojiljkovic MP, Bokonjic D, Dukic M: Standard antidotes along with sodium bicarbonate in organophosphate poisoning. Proceedings of chemical and biological medical treatment symposium (CBMTS); Spiez, Switzerland. 2002, April 28 - May 3
Koller M, Becker C, Thiermann H, Worek F: GC-MS and LC-MS analysis of nerve agents in body fluids: intra-laboratory verification test using spiked plasma and urine samples. J Chromatogr B Analyt Technol Biomed Life Sci. 2010, 878: 1226-1233. 10.1016/j.jchromb.2009.12.023.
Cole JB, Stellpflug SJ, Gross EA, Smith SW: Wide complex tachycardia in a pediatric diphenhydramine overdose treated with sodium bicarbonate. Pediatr Emerg Care. 2011, 27: 1175-1177. 10.1097/PEC.0b013e31823b0e47.
Valero A, Golan D: Accidental organic phosphorus poisoning: the use of propranolol to counteract vagolytic cardiac effects of atropine. Isr J Med Sci. 1967, 3: 582-584.
Monhart V, Fusek J, Brndiar M, Tlustakova M: Use of hemoperfusion in experimental intoxication with nerve agents. Artif Organs. 1994, 18: 770-772. 10.1111/j.1525-1594.1994.tb03317.x.
Yokoyama K, Ogura Y, Kishimoto M, Hinoshita F, Hara S, Yamada A, Mimura N, Seki A, Sakai O: Blood purification for severe sarin poisoning after the Tokyo subway attack. JAMA. 1995, 274: 379-
Rothschild L, Bern S, Oswald S, Weinberg G: Intravenous lipid emulsion in clinical toxicology. Scand J Trauma Resusc Emerg Med. 2010, 18: 51-10.1186/1757-7241-18-51.
Zhou Y, Zhan C, Li Y, Zhong Q, Pan H, Yang G: Intravenous lipid emulsions combine extracorporeal blood purification: a novel therapeutic strategy for severe organophosphate poisoning. Med Hypotheses. 2010, 74: 309-311. 10.1016/j.mehy.2009.09.001.
Bania TC, Chu J, Stolbach A: The Effect of Intralipid on organophosphate toxicity in mice. Acad Emerg Med. 2005, 12 (Suppl. 1): 7-12.
Pajoumand A, Shadnia S, Rezaie A, Abdi M, Abdollahi M: Benefits of magnesium sulfate in the management of acute human poisoning by organophosphorus insecticides. Hum Exp Toxicol. 2004, 23: 565-569. 10.1191/0960327104ht489oa.
Fuchs-Buder T, Tassonyi E: Magnesium sulphate enhances residual neuromuscular block induced by vecuronium. Br J Anaesth. 1996, 76: 565-566. 10.1093/bja/76.4.565.
Eddleston M, Buckley NA, Eyer P, Dawson AH: Management of acute organophosphorus pesticide poisoning. Lancet. 2008, 371: 597-607. 10.1016/S0140-6736(07)61202-1.
Okayama H, Aikawa T, Okayama M, Sasaki H, Mue S, Takishima T: Bronchodilating effect of intravenous magnesium sulfate in bronchial asthma. JAMA. 1987, 257: 1076-1078. 10.1001/jama.1987.03390080066032.
Ross MC, Broomfield CA, Cerasoli DM, Doctor BP, Lenz DE, Maxwell DM, Saxena A: Chapter 7: Nerve agent bioscavenger: Development of a new approach to protect against organophosphorus exposure. Textbooks of military medicine ,medical aspects of chemical warfare. Edited by: Lenhart MK, Tuorinsky SD. 2008, Washington, DC: The Office of the Surgeon General at TMM Publications, 243-259.
Pazooki S, Solhi H, Vishteh HR, Shadnia S, Beigi MJ: Effectiveness of fresh frozen plasma as supplementary treatment in organophosphate poisoning. Med J Malaysia. 2011, 66: 342-345.
Pichamuthu K, Jerobin J, Nair A, John G, Kamalesh J, Thomas K, Jose A, Fleming JJ, Zachariah A, David SS: Bioscavenger therapy for organophosphate poisoning - an open-labeled pilot randomized trial comparing fresh frozen plasma or albumin with saline in acute organophosphate poisoning in humans. Clin Toxicol (Phila). 2010, 48: 813-819. 10.3109/15563650.2010.518970.
Desire B, Saint-Andre S: Interaction of soman with beta-cyclodextrin. Fundam Appl Toxicol. 1986, 7: 646-657.
Desire B, Saint-Andre S: Inactivation of sarin and soman by cyclodextrins in vitro. Experientia. 1987, 43: 395-397. 10.1007/BF01940424.
Wille T, Tenberken O, Reiter G, Muller S, Le Provost R, Lafont O, Estour F, Thiermann H, Worek F: Detoxification of nerve agents by a substituted beta-cyclodextrin: application of a modified biological assay. Toxicology. 2009, 265: 96-100. 10.1016/j.tox.2009.09.018.
Collombet JM, Four E, Burckhart MF, Masqueliez C, Bernabe D, Baubichon D, Herodin F, Lallement G: Effect of cytokine treatment on the neurogenesis process in the brain of soman-poisoned mice. Toxicology. 2005, 210: 9-23. 10.1016/j.tox.2005.01.013.
Collombet JM, Beracochea D, Liscia P, Pierard C, Lallement G, Filliat P: Long-term effects of cytokine treatment on cognitive behavioral recovery and neuronal regeneration in soman-poisoned mice. Behav Brain Res. 2011, 221: 261-270. 10.1016/j.bbr.2011.03.006.
Gaydess A, Duysen E, Li Y, Gilman V, Kabanov A, Lockridge O, Bronich T: Visualization of exogenous delivery of nanoformulated butyrylcholinesterase to the central nervous system. Chem Biol Interact. 2010, 187: 295-298. 10.1016/j.cbi.2010.01.005.
Aracava Y, Pereira EF, Akkerman M, Adler M, Albuquerque EX: Effectiveness of donepezil, rivastigmine, and (+/−)huperzine A in counteracting the acute toxicity of organophosphorus nerve agents: comparison with galantamine. J Pharmacol Exp Ther. 2009, 331: 1014-1024. 10.1124/jpet.109.160028.
Teran-MacIver M, Larson K: Implication of chemical biological terrorist event for children and pregnant women. MCN. 2008, 33: 224-232. 10.1097/RLU.0b013e31815976ca.
Pediatric Expert Advisory Panel Participants: Atropine use in children after nerve gas exposure. Pediatric Expert Advisory Panel(PEAP) Addressing terrorism, Disaiter and public health emergency. 2004, New York: Columbia University Maliman School of Public Health, National Center for Disaster Preparedness, 1-8.
Bajgar J, Fusek J, Kassa J, Kuca K, Jun D: Chemical aspects of pharmacological prophylaxis against nerve agent poisoning. Curr Med Chem. 2009, 16: 2977-2986. 10.2174/092986709788803088.
Weinbroum AA, Rudick V, Paret G, Kluger Y, Ben Abraham R: Anaesthesia and critical care considerations in nerve agent warfare trauma casualties. Resuscitation. 2000, 47: 113-123. 10.1016/S0300-9572(00)00216-1.
Sogorb MA, Vilanova E, Carrera V: Future applications of phosphotriesterases in the prophylaxis and treatment of organophosporus insecticide and nerve agent poisonings. Toxicol Lett. 2004, 151: 219-233. 10.1016/j.toxlet.2004.01.022.
Wolfe AD, Rush RS, Doctor BP, Koplovitz I, Jones D: Acetylcholinesterase prophylaxis against organophosphate toxicity. Fundam Appl Toxicol. 1987, 9: 266-270.
Broomfield CA, Lockridge O, Millard CB: Protein engineering of a human enzyme that hydrolyzes V and G nerve agents: design, construction and characterization. Chem Biol Interact. 1999, 119–120: 413-418.
Bajgar J, Kuca K, Fusek J, Jun D, Bartosova L: Cholinesterase reactivators as prophylactics against nerve agents. Curr Bioact Compd. 2010, 6: 2-8. 10.2174/157340710790711773.
Bajgar J, Fusek J, Sevelova L, Kassa J: Original transdermal prophylactic antidote against nerve agents-TRANSANT. Chemical and biological medical treatment symposium; Spiez, Switzerland. 2004, 14-25–30 April